What is the clinical significance of the summed difference score (SDS) on nuclear cardiac stress imaging?

Clinical Significance of Summed Difference Score (SDS) on Nuclear Cardiac Stress Imaging

The summed difference score (SDS) is a critical prognostic marker that quantifies the extent of reversible myocardial ischemia, with values ≥2 indicating clinically significant ischemia and values ≥10% of left ventricular myocardium (or SDS ≥4-5) identifying patients at high risk for cardiac death and myocardial infarction who may benefit from invasive management.

Understanding SDS and Risk Stratification

The SDS represents the difference between summed stress score (SSS) and summed rest score (SRS), quantifying reversible perfusion defects that indicate viable but jeopardized myocardium 1. This score directly correlates with cardiovascular outcomes:

Risk Categories Based on SDS:

• SDS = 0-1: No significant ischemia; annual cardiac death/MI risk <1% 1
• SDS = 2-4: Mild ischemia; intermediate risk
• SDS ≥5: Moderate-to-severe ischemia; annual cardiac death/MI risk ≥5% 1

The critical threshold is SDS ≥2, which defines clinically significant ischemia 2. However, for prognostic and management decisions, reversible defects encompassing ≥10% of myocardium (approximately SDS ≥4-5) indicate moderate abnormality, while ≥15% (approximately SDS ≥7-8) indicates severe abnormality 1.

Prognostic Implications

Mortality and Morbidity Risk:

The extent of ischemia quantified by SDS forms an effective prognostic score for cardiac mortality 1. Rates of cardiac ischemic events increase proportionally with SDS values, with moderate-to-severe abnormalities (SDS ≥5-8) associated with annual cardiovascular death or MI risk ≥5% 1.

In post-PCI patients, the SDS independently predicts long-term outcomes: patients with SDS 0 had 17% critical event rates, SDS 1-4 had 29%, and SDS >4 had 69% event rates over 4 years 3. Each 1-point increase in SDS was an independent predictor of critical events 3.

Clinical Decision-Making Thresholds:

• SDS <2: No significant ischemia; medical management appropriate
• SDS 2-4: Mild ischemia; consider intensified medical therapy
• SDS ≥5-8: Moderate-to-severe ischemia; strongly consider invasive coronary angiography and potential revascularization 1

Important Clinical Considerations

Age and Population-Specific Factors:

In very elderly patients (≥85 years), SDS ≥9 (corresponding to summed stress score ≥9) significantly predicts perioperative major adverse cardiac events 4. The prognostic value remains robust across age groups, though interpretation must account for higher baseline comorbidity in elderly populations 1.

Gender Differences:

In women ≤65 years with high trait anxiety, SDS values may be significantly elevated and require careful clinical correlation 5. The prognostic models differ by gender and SDS severity, with moderate-to-severe SSS being the most significant predictive variable across all SDS categories in women 6.

Silent vs. Symptomatic Ischemia:

SDS is the only independent predictor of silent ischemia (odds ratio 0.64 per unit increase) 3. Silent ischemia (62% of ischemic cases post-PCI) predicts worse outcomes than no ischemia but tends toward better outcomes than symptomatic ischemia, closely related to SDS extent 3.

Pre-test Probability Context:

In patients with low or intermediate pre-test probability of CAD, ischemia is unlikely with SDS <4 2. This threshold helps avoid false-positive interpretations in lower-risk populations.

Common Pitfalls to Avoid

1. Don't dismiss SDS 2-3 as insignificant: While below the moderate ischemia threshold, these values still indicate reversible ischemia requiring medical optimization and follow-up 2, 7

2. Don't rely on SDS alone: Always integrate with SSS (extent of total perfusion abnormality), left ventricular ejection fraction, transient ischemic dilation, and clinical risk factors 1

3. Don't ignore normal SDS with high SSS: Fixed defects (high SSS, low SDS) predict long-term cardiac events even without acute ischemia 8

4. Don't apply exercise-derived thresholds to pharmacologic stress: Pharmacologic stress patients have nearly 2-fold higher event rates than exercise patients with similar SDS values due to greater comorbidity 1

Integration with Other Risk Markers

The SDS provides incremental prognostic value beyond clinical data and should be interpreted alongside:

• Post-stress LVEF reduction ≥5% or global LVEF <45%
• Transient ischemic LV dilation
• Increased lung or right ventricular uptake
• Multiple defects in different coronary territories 1

When combined with high-risk plaques on coronary CTA, SDS ≥2 significantly increases predictive value for cardiac events beyond either test alone (model Chi-square 17.4 vs. 9.4, P=0.005) 9.